NEJMæ¥æ¬å½å çã¯ï¼å¿ è¦ãªè«æã«ç°¡åã«ã¢ã¯ã»ã¹ã§ããããã主è¦è«æã¢ãã¹ãã©ã¯ãããç®æ¬¡ããThis Week at NEJM.orgããï¼æ¥æ¬èªè¨³ã«ã¦ãæä¾ãã¦ãã¾ãï¼ ORIGINAL ARTICLES III æ EGFR å¤ç°é½æ§èºçã«å¯¾ãããªã·ã¡ã«ããã Osimertinib in Stage III EGFR-Mutated Lung Canceråé¤ä¸è½ III æ EGFR å¤ç°é½æ§éå°ç´°èèºçã«å¯¾ããåå¦æ¾å°ç·çæ³å¾ã«ï¼ãªã·ã¡ã«ããããæä¸ããæ£è ã§ã¯ï¼2 å¹´ç¡å¢æªçåçã 65%ã§ãã£ãã®ã«å¯¾ãï¼ãã©ã»ããæä¸ããæ£è ã§ã¯ 13%ã§ãã£ãï¼ ãªãªã¸ãã«ãµã¤ãæ¥æ¬èªã¢ãã¹ãã©ã¯ã æèé害ã«ãããèªç¥ã¨éåã®è§£é¢ Cognitive Motor Dissociation in Disorders of Consciousnessæ示ã«å¯¾ãã¦è¦³å¯å¯è½ãªåå¿ããªãã£ãæè
ãµã¼ãã¹çµäºã®ãç¥ãã ãã¤ãYahoo! JAPANã®ãµã¼ãã¹ããå©ç¨ããã ãèª ã«ãããã¨ããããã¾ãã ã客æ§ãã¢ã¯ã»ã¹ããããµã¼ãã¹ã¯æ¬æ¥ã¾ã§ã«ãµã¼ãã¹ãçµäºãããã¾ããã ä»å¾ã¨ãYahoo! JAPANã®ãµã¼ãã¹ããæ顧ãã ããã¾ãããããããããé¡ããããã¾ãã
æ²»çã¨äºé²ã両輪ã«ãããä¸äººãã²ã¨ãã®æ³ããã«èª å®ã«åãåã姿å¢ã大åã«ãã¦ãã¾ãã ç§ãã¡ãåãåãã®ã¯ãã²ã¨ãã§ããç æ°ã®ä¸å®ãæ±ããæ¹ãæ¤æ»ãæãæ¹ãããããæ³ãã¯éãã¾ãããã§ããéãããã®å¿ã«å¯ãæ·»ãããã å½ç¶ãå»çç¾å ´ã«ããã¦ã¯ãå ¨ã¦ã®ãå¸æãå¶ãããã¨ã¯ã§ãã¾ãããããã§ããå»çã®å ¨ã¦ããµã¼ãã¹ã¨èããããªãã«ãã£ãé¸æè¢ãææ¡ãã¦ããã¾ãã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}